If the page does not redirect, click here
Combination breast cancer therapy targets tumor cells and the blood vessels that feed them
Between 30 and 40 percent of human breast cancers express a defective (mutant) form of p53, a protein that helps cancer cells proliferate and grow. Researchers found that combining a cancer therapy, which activates p53 and is currently under a clinical trial, with a second drug therapy that helps suppress tumor blood vessels found in cancer cells, can significantly reduce breast cancer tumors while causing cancer cell death.